# A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

> **NCT05618808** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 373 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** REGN9933
- **DRUG:** Enoxaparin
- **DRUG:** Apixiban

## Key facts

- **NCT ID:** NCT05618808
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-24
- **Primary completion:** 2024-05-27
- **Final completion:** 2024-05-27
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618808, "A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05618808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*